NKTR - Director at Nektar Therapeutics Acquires Company Stock Options Worth 85000 Shares | Benzinga
Robert Jeffrey Ajer, Director at Nektar Therapeutics (NASDAQ:NKTR), reported a large acquisition of company stock options on September 21, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Ajer, Director at Nektar Therapeutics, a company in the Health Care sector, was just awarded stock options worth 85,000 shares of NKTR. The options give Ajer the right to buy the company's stock at $0.68 per share.
Nektar Therapeutics shares are trading down 1.44% at $0.7 at the time of this writing on Thursday morning. Since the current price is $0.7, this makes Ajer's 85,000 shares ...